Quelling of Excitotoxicity in Acute Stroke With Ketamine
Key facts
- Where
- Wynnewood, United StatesSee the site
- Phase
- Phase 2/3
Where in United States
- Lankenau Medical CenterWynnewood, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Lower Merion Neurology Research Foundation
- Trial code
- NCT03223220
- Record updated
- 18 December 2023
- Original description
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.Read full original descriptionShow less
The investigators plan to undertake a phase II study to investigate the efficacy and side effects of intravenous ketamine to reduce neuroexcitotoxicity, and thus provide neuroprotection in patients diagnosed with acute ischemic stroke.
Inclusion: All patients who are 18 years or older, presenting or admitted to the study site with acute ischemic stroke, up to 24 hours since their last known well time; An MRI evidence of acute ischemic infarct on the diffusion-weighted imaging with ADC correlate; Pre-stroke modified Rankin scale of 0-2; Patient should be willing to participate in the study by providing a written consent himself/herself or through a proxy.
Exclusion: Known hypersensitivity or adverse reaction to prior administration of Ketamine; Pre-stroke modified Rankin scale of 3 or above; Pre-existing psychiatric illness; Intracranial hemorrhage of any type at presentation; Seizure at onset of symptoms; Sustained uncontrolled hypertension defined as Systolic Blood pressure greater than 185 mmHg or Diastolic Blood Pressure greater than 110 mmHg, despite administration of antihypertensive medications; Eligibility to receive IV Alteplase or intra-arterial thrombectomy/embolectomy; Longer than 24 hours since last known well time; Pregnant or lactating females; Inability/refusal to provide consent by the patient or through a proxy.